Millennium Management
URGN icon

Millennium Management’s UroGen Pharma URGN Stock Holding History

Millennium Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,000
Closed -$898K – 6482
2025
Q3 		$898K Buy
45,000
+100
+0.2% +$1.8K ﹤0.01% 4700
2025
Q2 		$615K Buy
+44,900
New +$431K ﹤0.01% 4759

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management's URGN Position: Q1 2026 in Review

Millennium Management reduced its UroGen Pharma (URGN) stake by 40% in Q1 2026, selling an estimated $4.97M and leaving 370,898 shares worth $6.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2610.

Millennium Management first reported a position in URGN in Q4 2017 and has held it in 32 quarters since. The position peaked at $29.3M in Q3 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Millennium Management held 370,898 shares of UroGen Pharma worth $6.67M as of Q1 2026.
  • Millennium Management sold 248,054 UroGen Pharma shares in Q1 2026, an estimated $4.97M.
  • UroGen Pharma made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2610 holding.
  • Millennium Management first reported a position in UroGen Pharma in Q4 2017 and has held it in 32 quarters since.
  • Millennium Management's UroGen Pharma position peaked at $29.3M in Q3 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.